Back
Speaker illustration

undefined undefined undefined

Presentations Articles

Cardiovascular outcomes of sodium glucose co-transporter-2 inhibitor treatment in cancer patients receiving anthracycline chemotherapy: a systematic review and meta-analysis

Event: ESC Congress 2025

Topic: Diagnosis and Management of Cardiovascular Disease in Patients with Cancer

Session: Cardio-oncology: around the world

Access
Like
Thumbnail

Effects of sodium-glucose co-transporter-2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis

Event: ESC Congress 2025

Topic: Pharmacotherapy

Session: Heart failure therapy across the spectrum

Access
Like
Thumbnail

Effects of sodium glucose cotransporter 2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis

Event: ESC Asia 2022 with APSC & AFC

Topic: Cardiovascular Pharmacotherapy

Session: Pharmacology and Pharmacotherapy

Access
Like
Thumbnail

Effects of sodium glucose cotransporter 2 inhibitors on the risk of hyperkalemia in patients on mineralocorticoid receptor antagonist: a systematic review and meta-analysis

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Chronic heart failure treatment

Access
Like
Thumbnail

Efficacy of sodium glucose cotransporter-2 inhibitors for heart failure with preserved and with mildly reduced ejection fraction: a systematic review and meta-analysis

Event: Heart Failure 2022

Topic: Pharmacotherapy

Session: Heart Failure ePosters - focus on Chronic Heart Failure 3

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources